Research programme: chronic pain therapeutic - Daewoong PharmaceuticalAlternative Names: DWJ 208
Latest Information Update: 07 Oct 2015
At a glance
- Originator Daewoong Pharmaceutical
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Pain
Most Recent Events
- 07 Oct 2015 Preclinical development for Chronic pain is ongoing in South Korea
- 18 Mar 2014 Preclinical trials in Pain in South Korea (unspecified route)
- 10 Oct 2012 Early research is ongoing in South Korea